Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
CANTON, Mass., January 11, 2021 – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has granted ReNu®, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis (OA), Regenerative Medicine Advanced Therapy (RMAT) designation. Read more: Organogenesis ReNu® Receives FDA Regenerative Medicine [...]